Carlyle, Brighton Park invest $200 million in Indian healthtech company Indegene

• Indegene is a 23-year-old healthtech solutions provider with interests across pharmaceuticals, biotechnology solutions, and medical devices.
• Both the firms will pick up minority stakes in Indegene, through a primary as well as secondary transaction.
• According to reports, Indegene’s valuation has jumped to $700 million.

American private equity giant The Carlyle Group and investment firm Brighton Park have pumped in $200 million into Indian healthtech firm Indegene. Both the firms will pick up minority stakes in Indegene, through a primary as well as secondary transaction by buying out existing investors.

According to reports, Indegene’s valuation has jumped to $700 million after the deal.

Indegene is a 23-year old is a healthtech solutions provider with interests across pharmaceuticals, biotechnology solutions, and medical devices. The company has over 3,000 employees in offices across India, North America, Europe, China and Japan.

With the latest investment, the company now aims to expand its global presence and M&A activities.

“Carlyle’s commitment to the healthcare sector with their global network and deep pharmaceutical expertise, coupled with Brighton Park’s deep experience in the technology sector and nuanced understanding of our space, makes the two firms the ideal partners to support our company’s continued growth,” said Manish Gupta, co-founder and CEO of Indegene.

The company also claims that its revenues grew at around 25% every year for the last ten years.

Meanwhile, Carlyle has been ramping up its India presence especially in the health sector. The firm invested in Piramal Pharma; a pure-play animal healthcare company SeQuent; Delhi Medanta Medicity Hospital, and diagnostic center and laboratory operator Metropolis Healthcare. It has also invested in startup unicorns like Delhivery.

One of Carlyle’s senior advisors is Aditya Puri, the former HDFC Bank CEO, who has recently joined the PE firm.